gogogogogogogo
Eli Lilly's stock price hit a record high and analysts raised their target prices.
On October 22, Eli Lilly's stock price bucked the trend and rose nearly 4%, hitting a new historical high, with a cumulative increase of more than 22% since the beginning of the year. Analysts raised their price targets due to strong demand for Mounjaro and Zepbound, as well as capital investment to expand global production facilities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments